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Glioblastoma (GBM) with oligodendroglioma component (GBMO) is a newly described GBM subtype in the 2007
World Health Organization classification. However, its biological and genetic characteristics are largely unknown.
We investigated the clinicopathological and molecular features of 34 GBMOs and compared the survival rate of
these patients with those of patients with astrocytoma, oligodendroglioma, anaplastic oligoastrocytoma (AOA),
and conventional GBMs in our hospital. GBMO could be divided into two groups based on the presence of an
IDH1 mutation. The IDH1 mutation was more frequently found in secondary GBMO, which had lower frequencies
of EGFR amplification but higherMGMTmethylation than the wild type IDH1 group, and patients with mutant IDH1
GBMO were on average younger than those with wild-type IDH1. Therefore, GBMO is a clinically and molecularly
heterogeneous subtype, largely belonging to a proneural and classical subtype of GBM. The survival rate of GBMO
patients itself was worse than that of AOA patients but not significantly better than that of conventional GBM
patients. GBMO survival was independent of the dominant histopathological subtype i.e., astrocyte-dominant or
oligodendroglioma -dominant, but it was significantly associated with the IDH1 mutation and MGMT methylation
status. Therefore, GBMO should be regarded as a separate entity from AOA and must be classified as a subtype of
GBM. However, further study is needed to determine whether it is a pathologic variant or a pattern of GBM
because GBMO has a similar prognosis to conventional GBMs.
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Glioblastoma (GBM) is the most common primary brain tumor
and is associated with a short survival time of approximately 14.6 to
15.1 months following current multimodal treatment [1]. GBM is
known to have heterogeneous histological features, which allow
further subdivision into variants. GBM with oligodendroglioma
component (GBMO) is a new variant that has been added to the
updated 2007 World Health Organization (WHO) classification of
tumors of the central nervous system (CNS) [2]. In the WHO blue
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significant subtype with sufficiently different biological behavior than
the main entity” [3]. Histological pattern was defined as “a particular
differentiation pattern that does not correspond to a unique clinical/
biological behavior” [3].
Two features distinguish this entity as a new variant. First, it contains
foci that resemble oligodendroglioma on histological examination.
Second, this subgroup shows a biological difference from preexisting
tumor types in large studies [4,5], because anaplastic oligoastrocytoma
(AOA) with necrosis is associated with a significantly worse prognosis
than AOA without necrosis, but is associated with a better overall
survival rate than that of conventional GBM patients (median overall
survival: AOAwith necrosis, 22.8months; AOA without necrosis, 86.9
months; GBM, 9.8 months). However, in 1996, Nelson et al. reported
a slightly better median survival in GBMO patients than in
conventional GBM patients (14.3 months vs. 10.4 months), which
was quoted by Vordermark et al. [6]. Therefore, AOA with necrosis has
been renamed GBMO, although at the consensus meeting there was
debate as to whether this should be sanctioned, as it is still not clearly
defined. Hence, collection of clinicopathological and biological data has
been necessary in order to accurately classify GBMO [7,8].
The reported biological behavior of GBMO has varied, with some
studies reporting a better survival rate for GBMO compared to
conventional GBM [6,9,10], whilst others have found no difference
[11–13]. There have been many studies to assess the difference
between GBMO and conventional GBM based on their clinicopath-Figure 1. Histopathological features of glioblastoma (GBM) with
transitional area of astrocytic and oligodendroglioma-like tumor. B) Th
cells with uniform round nuclei and perinuclear halos (giving a honeyc
irregular or elongated cells with pleomorphic nuclei, and D) necrosis, cological and molecular genetic characteristics [8,9,11,13–16]. Despite
this, there have been neither definitive diagnostic criteria nor a sufficient
description of the clinical and genetic features of GBMO until now.
Here, we report the genetic abnormalities of GBMOcases in our hospital
and compare our results with previously reported data to delineate the
genetic characteristics and biological behavior of this malignancy.
Materials and Methods
Tissue Samples
We selected cases that showed distinct morphological features of
both GBM and oligodendroglioma in the same tumor from the
pathology archives of the Department of Pathology, Seoul National
University Hospital, collected between July 2007 and January 2013.
Histopathological slides were reviewed independently by at least two
neuropathologists (S. H. Park and J. K. Myung), and representative
paraffin blocks were selected for the immunohistochemical and
genetic studies. All of the specimens contained a classic GBM area
with vascular hyperplasia and necrosis, together with oligodendroglial
morphology (Figure 1). The classic GBM area was designated as
astrocytic differentiation with glial fibrillary acidic protein-positive
cells as well as micro vascular hyperplasia and necrosis. The oligoden-
droglioma component was characterized by oligodendroglioma
morphology, including uniform round cells with rounded nuclei, a
perinuclear halo, and delicate capillaries forming a chicken-wire
pattern. Thirty-four brain tumors fulfilled the criteria of GBMO. Weoligodendroglioma component (GBMO). A) This picture shows
e oligodendroglioma component was composed of monomorphic
omb appearance). C) Concomitantly, the same tumor had sheets of
onsistent with glioblastoma area. (A–D: H&E, A: ×100, B–D:×200).
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component, as used in the studies by Ha et al. and Donahue et al.
[11,17], but sufficient counter-component was usually present in our
series of GBMOs. We strictly excluded the small cell variant of GBM.
Additionally, we sub-classified GBMO into two histopathological
subtypes according to the dominant component comprising N50% of
tumor. Astrocyte-dominant type (GBMO-A) and oligodendroglioma
dominant type (GBMO-O) accounted for 18 and 16 cases, respectively.
We then compared overall survival according to the dominant
histological subtype using Kaplan-Meier survival analysis. Secondary
GBMO was defined as those cases that had previous pathology-proven
lower grade tumors. We tested for the presence of the isocitrate
dehydrogenase 1/2 (IDH1/2) and B-Raf protooncogene (BRAF)V600E
mutations, amplification or high polysomy of epidermal growth factor
receptor (EGFR), homozygous deletion of 9p21.3, allelic loss of 1p/19q,
and O-6-methylguanine DNA methyltransferase (MGMT) gene
methylation in our series of GBMOs. Immunohistochemical staining
for IDH1 (H09) and other markers were performed in 34 cases.
This study was approved by the institutional review board of Seoul
National University Hospital (IRB No. 1310-008-521).
DNA Extraction
Tumor areas were manually micro-dissected using 6-μm unstained
tissue sections made from formalin-fixed and paraffin-embedded
(FFPE) tissue. DNA was isolated from the micro-dissected tissue
using a DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions.
Polymerase Chain Reaction (PCR)Amplification and Sequencing
of IDH1, IDH2, and BRAF V600E
Template DNA (1 μl) was added to 100 μl of PCR solution (10 μl of
10×MagnesiumTaq-High Fidelity [HF] buffer, 10 μl deoxynucleotide
triphosphate [dNTP] mixture with 2 mMmagnesium, 5 μl of 10 pmol
primer [×2], 1 μl of magnesium Taq-HF polymerase, and distilled
water). The IDH1-Forward(F)/IDH1-Rerverse(R), IDH2-F/IDH2-R,
and BRAF-F/BRAF-R primers (Supplementary Table 1) were used with
the following program: 35 cycles of 95°C for 30 seconds, 55°C for
30 seconds, and 72°C for 60 seconds for IDH1/IDH2 sequencing; and
35 cycles of 94°C for 45 seconds, 55°C for 45 seconds, and 72°C for
45 seconds for BRAF sequencing. The product sizes were 130-base pair
(bp) (IDH1), 293-bp (IDH2), and 200-bp (BRAF). Unincorporated
PCR primers and dNTPs were removed from the PCR products using a
Montage PCR Clean-up Kit (Millipore, Billerica, MA).
The purified products were sequenced using the same primers.
Sequencing was performed using a BigDye Terminator Cycle
Sequencing Kit v. 3.1 (Applied Biosystems, Foster City, CA). The
sequencing products were resolved on an Applied Biosystems model
3730XL Automated DNA Sequencing System.
Fluorescence In Situ Hybridization (FISH)
FISH with Vysis probes was used to assess 1p/19q, 9p21.3
(CDKN2A), and EGFR gene status. Sections (3 μm thick) were
deparaffinized in xylene, incubated with 0.3% pepsin in 10mMHCl at
37°C for 10minutes, boiledwith citrate buffer (pH6.0) in amicrowave,
incubated in 1 M NaSCN for 35 minutes at 80°C, immersed in the
pepsin solution, and fixed in 10% neutral buffered formalin.
Labeled locus-specific (LSI) EGFR/CEP7 dual-color probes
(Abbott Molecular), LSI CDKN2A/CEP9 dual-color probes (Abbott
Molecular), and 1p36/1q25 and 19q13/19p13 LSI dual-color probes(Abbott Molecular) were used according to the manufacturer’s
protocol. We applied the probe mixture to the slides and incubated
them in a humidified atmosphere with HYBrite (Abbott Molecular,
Des Plaines, IL) at 73°C for 5 minutes for simultaneous denaturation
of the probe and target DNA. Then, we cooled the samples to 37°C
and incubated for 19 hours to hybridize the probes and target DNA.
The slides were submerged in 0.4× SSC buffer/0.3% NP-40 for
2 minutes at room temperature, followed by 2× SSC/0.1%NP-40 for
5 minutes at 73°C.
The processing and analysis of the FISH studies were conducted as
described previously [18], as was the analysis of the chromosome 1p/19q
deletion and CDKN2A (9p21.3) [18,19]. For analysis of EGFR gene
status, at least 100 tumor cell nuclei were counted per case. High
polysomy (≥4 copies in ≥40% of cells) and gene amplification (the
presence of tight EGFR gene clusters and ≥2 EGFR copies per
chromosome or ≥15 EGFR copies per genome in ≥10% of analyzed
cells) was regarded as an EGFR-positive FISH result.
MGMT Methylation-Specific PCR (MSP) Analysis
Tumor DNA was extracted after manual micro-dissection from
FFPE, and MSP was conducted using an EZ DNA Methylation Kit
(Zymo Research, Irvine, CA) to determine the methylation status of
the MGMT promoter, as described previously [20].
Hematoxylin and Eosin (H&E) Staining
and Immunohistochemistry
FFPE (10% neutral buffered formalin, routinely processed, and
paraffin embedded) tissue sections (2–4 μm thick) were cut for H&E
staining and immunohistochemistry. Tissue sections were stained with
anti-IDH1 R132H (H09) monoclonal antibody (Dianova, Hamburg,
Germany) using a 1:20 dilution. Immunohistochemical staining was
carried out using a standard avidin–biotin peroxidase method.
Survival Analysis
We compared overall survival of GBMO to other gliomas,
including WHO grade II tumors (low grade oligodendroglioma,
LO, n = 39), WHO grade III tumors (anaplastic oligodendroglioma,
AO, n = 44; anaplastic oligoastrocytoma, n = 37), and conventional
GBM (n = 44). The clinical features of these patients are summarized
in Supplementary Table 2.
Statistical Analysis
The chi-square test and Fisher’s exact test were used to measure the
strength of interaction between two independent variables. An
independent t test was used to compare the mean age in the two
groups. Overall survival was estimated using the Kaplan–Meier survival
analysis, and was compared using the log-rank test. All statistical
analyses were performed with SPSS version 18 (Chicago, IL); P b .05
was considered significant.
Results
Clinicopathological Results
We identified GBMO tumors from 34 subjects whose ages ranged
from 19 to 77 years (mean age, 53.3 years). The ratio of men to
women was 3.25:1. The follow-up periods ranged from 1 month to
37 months (median 16.0 months). For post-operative treatment, 24
patients (70.6%) received concurrent chemoradiation therapy with
temozolomide treatment, six received either chemotherapy or
radiation therapy alone, and 5 received neither adjuvant treatment.
Translational Oncology Vol. 7, No. 6, 2014 Biology of glioblastoma with oligodendroglioma component Myung et al. 715GBMO was the primary tumor in 25 (73.5%) patients, and secondary
in 9 patients (26.5%). The primary tumors for the secondary GBMOs
were astrocytic tumors (grade 2 or 3) in 7 patients and oligoden-
droglioma in 2 patients. The clinical features of all patients are
summarized in Supplementary Table 3.
Molecular Studies
We found 13 (13/34; 38%) IDH1 (H09) positive cases, all of
which were found to carry a mutation in codon 132 of IDH1 on
direct sequencing. A 1p/19q co-deletion was found in three of 33
patient tumors (9.1%), and two of them (2/3, 66.7%) had
concomitant IDH1 mutations, but none of them showed positive
results on EGFR FISH or homozygous deletion of CDKN2A. EGFR
gene amplification or high polysomy were present in 13 cases (38.2%,
amplification in seven cases and high polysomy in six cases), and two
of them carried the IDH1 mutation. Nine (33.3%) of 27 cases
revealed homozygous deletion in CDKN2A (9p21.3), five of which
(5/9, 55.6%) had positive results on EGFR FISH and two (2/9,
22.2%) had the IDH1 mutation. Eighteen of 33 patient tumors
(54.5%) revealed methylation of theMGMT promoter. Of these, ten
of 18 patients (10/18, 55.6%) had the IDH1 mutation and five
patients (5/18, 27.8%) had positive results on EGFR FISH. The
BRAF V600E mutation was found in only one case. These results
are summarized in Supplementary Table 4.
We divided the GBMOs into two subgroups according to IDH1
mutation status. Patients with the IDH1 mutation were on average
younger than those without the mutation (46.5 years [range, 34 to
62 years] vs. 57.5 years [range, 19 to 77 years]; P b .05) (Table 1).
Both groups contained more men than women. Only one of 21 cases
(4.8%) of the wild-type IDH1 group involved secondary GBMO,
compared with eight cases (8/13, 61.5%) of the IDH1mutant group.
The frequency of EGFR gene abnormality was significantly higher in
the wild-type IDH1 group than in the IDH1mutant group (52.4% vs.
15.4%). In contrast, MGMT promoter methylation occurred signifi-
cantly more frequently in IDH1-mutant GBMOs than in IDH1-wild
type GBMOs (83.3% vs. 38.1%). However, 1p/19q co-deletion,
BRAF mutation, and PTEN loss rarely occurred, and were not
significantly different between IDH1 mutant- and IDH1 wild-type
GBMOs. The key findings were therefore that EGFR gene
abnormalities were negatively associated with IDH1 mutation (P =Table 1. Molecular Features of GBMO According to IDH1 Mutation
Variable Result IDH1 *
Mutation # (n
Age Mean (range) 46.5 (39-62)
N45 y 6
N60 y 1
Gender Male 9
Female 4
GBM type Primary GBMO 5/13 (38.5)
Secondary GBMO 8/13 (61.5%)
EGFR FISH Amplification (7)/high polysomy (6) 2/13 (15.4%)
CDKN2A FISH HD 3/10 (30.0%)
MGMT MSP Methylation 10/12 (83.3%
1p 19q FISH Co-deletion 2/13 (15.4%)
BRAF V600E * Mutation 1/10 (10.0%)
PTEN IHC Loss 3/13 (23.1%)
P53 IHC Positive 11/13 (84.6%
HP: high polysomy, FISH: fluorescence in situ hybridization, HD: homozygous deletion, MGMT-MSP:
* IDH1 and BRAF mutations were studied by direct sequencing.
# All IDH1 mutation was Arg132His..031) and MGMT methylation was positively associated with IDH1
mutation (P = .011). In addition, as described above, IDH1 mutant
GBMO had a higher MGMT methylation rate (83.3%); however,
about half (55.6%) of MGMT methylated tumors carried the IDH1
mutation. These results are summarized in Table 1.
Survival Analysis
The cumulative survival rate of patients with GBMO was worse
than that of AOA patients, but it was not significantly different from
that of patients with conventional GBM (Figures 2A, 3A, B).
Interestingly, patients with IDH1 wild-type AO showed interme-
diate survival between IDH1 wild-type LO and AOA patients
(Figure 2B). There was no prognostic difference between GBM and
GBMO regardless of whether the IDH1 mutation was present (P =
.203, Figure 2C). However, there was a distinct survival difference
according IDH1 mutation status, regardless of tumor type
(Figure 2D). We did not include AOAs in the Kaplan–Meier survival
analysis according to IDH1mutation status, because we did not study
IDH1 mutation status in all of the AOAs. Furthermore, there was no
survival difference with respect to treatment between age matched
patients with conventional GBM or GBMO (Figure 3B), primary or
secondary GBMO (Figure 3C), or dominant histological subtype
(Figure 3D). However, the cumulative survival rates of GBMO
patients with tumors carrying the IDH1mutation and the methylated
MGMT promoter were significantly better than the rates of patients
with IDH1 wild-type and MGMT unmethylated GBMOs
(Figure 3E, F). On multiple regression analysis, none of the above
mentioned clinicopathological parameters were associated with the
overall survival of GBMO patients except primary and secondary
nature of GBMO (P = .009).
Discussion
Clinical Aspects of GBMO
The reported incidence of GBMO varies between 11.9% and
17.6% [10,21], and in our hospital it was 14.0% (34 GBMO/243
GBM). Our cases of GBMO showed characteristics similar to those
described in previous reports. The overall mean age of GBMO
patients and of primary GBMO patients was similar to that of
patients with conventional GBM, although patients with secondary
GBMO were younger (45.3 years) than patients with primaryTotal P Value
= 13) Wild Type (n = 21)
57.5 (19-77) 53.3 (19-77) .007
17 23 .036
10 11 .007
17 26 .449
4 8
20/21 (95.2%) 25 (73.5%) .001
1/21 (4.8%) 9 (26.5%)
11/21 (52.4%) 13 (38.2%) .031
6/17 (35.3%) 9 (33.3%) .788
) 8/21 (38.1%) 18 (54.5%) .011
1/21 (4.8%) 3 (8.8%) .303
0/12 (0%) 1 (4.5%) .333
3/21(14.3%) 6 (17.6%) .528
) 15/21 (71.4%) 26 (76.5%) .569
O-6-methylguanine DNA methyltransferase-methylation specific PCR, IHC: immunohistochemistry.
Figure 2. Kaplan-Meier survival analysis of patients with low grade oligodendroglioma (LO), anaplastic oligodendroglioma (AO), anaplastic
oligoastrocytoma (AOA), gliobloastoma with oligodendroglial component (GBMO) and conventional glioblastoma (GBM). A) GBMO
patients had significantly shorter survival than those with AOAwithout necrosis, LO and AO, but had not better survival than conventional
GBM patients. B) As expected, patients with IDH1mutant tumors survived for longer than those with IDH1wild-type tumors. The patients
with IDH1 mutant AO survived longer than patients with wild-type AO and had similar survival to patients with IDH1 wild-type LO, and
patients with IDH1 wild-type AO had better survival than patients with GBMO or conventional GBM. C) A survival analysis of GBM and
GBMO patients according to IDH1mutation status revealed no statistically significant difference (P= .203). D) If all tumors are subdivided
according to IDH1 mutation status regardless of tumor type, patients with IDH1 mutant tumors survived for considerably longer than
those with IDH1wild-type tumors. We did not include AOAs in B and D because we did not study IDH1mutations in all of the AOA cases.
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secondary GBMO accounted for 26.5% of all GBMO cases, which
is a similar proportion to that previously reported (24% to 32%,
Table 2) but more frequent than secondary conventional GBM
(about 5%). Also consistent with previous reports was the
predominance of male patients with primary and secondary GBMO,
and conventional GBM (Supplementary Table 5) [9,21].
Molecular Aspects of GBMO
IDH1 Mutation. The frequency of IDH1 was slightly higher
(38.2%) in our series than previous reports (Supplementary Table 4
and Table 2). IDH1 mutation is the most important molecular event
in low-grade glioma and secondary GBMs [19,22,23]. Joseph et al.
also suggested that mutation of the IDH1 gene could be a key step in
the tumorigenesis of GBMO [24]. However, as expected, fewer
primary GBMOs in this study carried an IDH1 mutation than
secondary GBMOs (20% vs. 88.9%) (Supplementary Table 5).
While this figure is a simplistic depiction of the difference in IDH1
mutation rates between GBMO and conventional GBM, and
between primary and secondary GBMO, it provides further evidencefor a similar heterogeneity in IDH1 mutation status in these tumor
types. This might also explain the heterogeneous clinical and
molecular features of GBMO.
Other Molecular Profiles of GBMO. Kraus et al. and He et al.
found that GBMOs more frequently showed a 1p and 19q deletion,
but less commonly exhibited loss of heterozygosity (LOH) of 10q,
loss of PTEN, and homozygous deletion of CDKN2A compared to
conventional GBM [8,21]. According to the He et al. report, there
was LOH 1p in 40%, LOH 19q in 60%, EGFR amplification in
44%, p16 deletion in 48%, LOH 10q in 64%, PTEN loss in 20%,
and TP53 mutation in 24% of GBMOs [21]. We found far less
co-deletion of 1p/19q (9.1%) in our study of 34 GBMOs, but a
similar rate of EGFR amplification or high polysomy (38.2%) and
homozygous deletion of 9p21.3 (CDKN2A) (33.3%). Kraus et al. and
Pinto et al. found that the 1p/19q co-deletion was present in as few as
10% of GBMOs [8,25], which is similar to the observed 1p/19q
co-deletion rate (8.8%) in our study. Co-deletion of 1p/19q is an
important diagnostic and prognostic factor in oligodendroglioma [26].
Based on our findings, GBMOhas a different genetic background from
that of pure oligodendroglial tumors.
Figure 3. A, B) The survival rate of GBMO patients was similar to that of conventional GBM patients, even with age- and treatment
matching. C, D) The survival rate of GBMO patients is not statistically different regardless of whether it is primary or secondary, or whether
it has a dominant oligodendroglioma or astrocytic component. E, F) However, patients with IDH1mutant andMGMTmethylated GBMO
had significantly better survival than patients with GBMO without IDH1 mutation or MGMT methylation.
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ranged from 44.4% to 47% [9,16], which is similar to that of
conventional GBM; however, we found a higher rate of MGMT
methylation (54.5%). When we divided the GBMO cases into IDH1
wild type and mutant subgroups, the latter showed an even higher
frequency (83.3%) of MGMT methylation, but a lower frequency
(15.4%) of EGFR gene amplification. The mean age of the IDH1
mutant GBMO group was younger than that of the wild type IDH1
GBMO group (46.5 years vs. 57.5 years) and the former had a higher
proportion of secondary GBMO (61.5% vs. 4.8%).In 2010, four molecular classifications of GBM based on the
Cancer Genome Atlas Network data were widely accepted [27].
According to that classification, classical, neural, proneural, and
mesenchymal subtypes were defined by mutations and differing
expression levels of a number of genes including EGFR, neurofi-
bromin1 (NF1), platelet-derived growth factor receptor alpha
polypeptide (PDGFRA), and IDH1. GBMO carrying an IDH1
mutation in our study shared similar molecular profiles to the
proneural type of GBM, whilst wild-type IDH1 GBMO belonged to
the classical type of GBM. Similar results were also reported by Hegi
Table 2. Summary of Clinical and Molecular Features of GBMO from the Literatures and our Cases
Variable Appin et al. Ha et al. Wang et al. Our Series
Case number 28 42 40 34
Primary GBM 19 (67.9%) 32 (76.2%) Not record 25 (73.5%)
Secondary GBM 9 (32.1%) 10 (23.8%) Not record 9 (26.5%)
Mean age (range) 50.7 49.2 (26-73) 43.2 (19-62) 53.3 (19-77)
Sex ratio(M:F) 3:1 2:1 (28:14) 23:17 3.25:1
IDH1 mutation Positive 7/20 (35%) 11/42 (26.2%) 9/29 (31.0%) * 13/34 (38.2%)
EGFR FISH amp 6/26(23%) Not record 19 (47.5%)-IHC 13/34 (38.2%)
1p 19q FISH Co-deletion 8/27 (29.6%) 7/39 (17.9%) 1/28 (3.6%) 3/33(9.1%)
MGMT MSP Methylation 9/20 (45.6%) 13/42 (31.0%) 8/18 (44.4%) 18/33 (54.5%)
CDKN2A FISH HD No record No record No record 9/27 (33.3%)
GBMO: glioblastoma with oligodendroglioma component, GBM:glioblastoma, IDH1: isocitrate dehydrogenase 1, amp: amplification, FISH: fluorescence in situ hybridization, IHC:
immunohistochemistry, MGMT-MSP: O-6-methylguanine DNA methyltransferase-methylation specific PCR.
* Sequencing.
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mutation status is taken into consideration (Table 1). Therefore,
GBMO should be classified according to its molecular features when
investigating differences in clinical findings and prognosis.
Sequencing for the BRAF V600E mutation was performed in only
22 cases of GBMO, and only a single mutation was found (1/22,
4.5%), which is concordant with previously published data [9,11,13].
The BRAF V600E mutation rate in GBMO has not been
established. Our previous study of BRAF V600E in diverse CNS
tumors revealed a low mutation rate (3.7–8.6%) in GBMs and
oligodendroglial tumors [18]. Therefore, we believe that the BRAF
V600E mutation does not have particular importance in the
pathogenesis of GBM and GBMO. In Table 2, we have summarized
the diverse molecular genetic profiles of GBMO that have been
previously published [9–11].
Survival of Patients with GBMO
GBMO was initially considered to be a separate entity because it
was associated with a worse prognosis than WHO grade III mixed
oligoastrocytoma, but a better survival rate than conventional GBM
[6,9,10]. However, some studies stressed that better survival might be
associated with chemosensitive molecular genetic alterations of
oligodendroglioma component [6,25]. Wang et al. found that
aggressive treatment did not generally improve the survival of
GBMO patients, although it significantly reduced the mortality of
patients with conventional GBM [9]. In our series, the cumulative
survival of GBMO patients was clearly worse than that of patients
with AOA, but it was not significantly different from the survival of
patients with conventional GBM (Figure 3, A and B). Furthermore,
there was no survival difference between primary and secondary
GBMO patients and between those with GBMO-A and GBMO-O
subtypes, although secondary GBMO had tendency of better
prognosis than primary GBMO (Figure 3, C and D). However,
IDH1 mutation status or MGMT methylation status were important
predictive factors for survival. The overall survival of patients with
IDH1 mutant orMGMT methylated GBMO was significantly better
than that of the patients with wild type IDH1 and MGMT
unmethylated GBMO (Figure 3E and F). Our findings concur
with those of Ha et al.’s results in that the outcome of GBMO in
general was not different from conventional GBMO; however, their
finding that GBMO-O patients had a significantly better outcome
than patients with GBMO-A (cutoff: N50%) was not in agreementwith ours [11]. Elmahdi et al. also observed that GBMO had a similar
clinical profile to conventional GBM, even with respect to age
distribution and survival [12]. Conversely, Appin et al. found that
GBMO patients had a longer median survival than conventional
GBM patients (16.2 vs. 8.1 months), although this might have
reflected a younger age at presentation and a 1p deletion [10].
To summarize, our findings show that GBMO is genetically
heterogeneous in a similar manner to conventional GBM, which
largely belongs to the proneural and classical subtype. The survival
rate of GBMO patients in general is significantly worse than that of
AOA patients, but not different from that of conventional GBM
patients. However, as expected, GBMO patients with IDH1 mutant
or MGMT methylated tumors survived longer than those with
wild-type IDH1 or MGMT unmethylated tumors. Therefore,
GBMO should be regarded as a separate entity from AOA without
necrosis, and should be considered as a GBM subtype. Moreover,
GBMO with the IDH1 mutation and/or MGMT methylation
should be considered as a biologically significant variant since its
prognosis and clinical features differ from that of GBMO without the
IDH1 mutation and/or MGMT methylation. For these reasons,
IDH1 mutation and MGMT methylation status should be considered
when we make a diagnosis of GBMO. Despite this, the
histopathological dominant subtype did not show prognostic value.
In addition, on multivariate analysis, none of the clinical, genetic, or
molecular parameters were associated with the survival of GBMO
patients except primary or secondary status. A review of more cases is
needed to determine whether GBMO is a pathologic variant or a
pattern of GBM because our study failed to show any significant
differences between GBMO and conventional GBM.
The previous reports showed that the prognosis of GBMO was
better than that of GBM might be affected by high proportion of
IDH1 mutated or MGMT methylated or secondary tumors among
GBMOs than those of conventional GBM.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.10.002.
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